Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib

Published:2022-02-23 Issue:6 Volume:24 Page:1029-1031
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Papusha Ludmila¹^ORCID,Zaytseva Margarita¹^ORCID,Panferova Agnesa¹^ORCID,Druy Alexander¹^ORCID,Valiakhmetova Andge¹^ORCID,Artemov Anton¹,Salnikova Ekaterina¹^ORCID,Kislyakov Alexey¹²,Imyanitov Evgeny³⁴^ORCID,Karachunsky Alexander¹^ORCID,Maschan Alexey¹^ORCID,Hwang Eugene I⁵⁶,Novichkova Galina¹^ORCID,Packer Roger J⁵⁶⁷^ORCID

Affiliation:

1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology , Moscow , Russian Federation

2. Morozov City Children Hospital , Moscow , Russian Federation

3. St. Petersburg Pediatric Medical University , St. Petersburg , Russian Federation

4. N.N. Petrov Institute of Oncology , St. Petersburg , Russian Federation

5. Division of Oncology, Children’s National Hospital , Washington, DC , USA

6. Brain Tumor Institute , Washington, DC , USA

7. Center for Neuroscience and Behavioral Medicine , Washington, DC , USA

Funder

“Science for Children” and the Russian Science Foundation

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

https://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noac026/42588937/noac026.pdf

Reference10 articles.

1. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas;Stucklin;Nat Commun.,2019

2. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types;Sievers;Acta Neuropathol.,2021

3. Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3);Coccé;Genes Chromosomes Cancer.,2016

4. ROS1 inhibitor entrectinib use in relapse/refractory infantile glioblastoma with positive ROS1 fusion—a case report with promising response;Ku;Neuro Oncol.,2020

5. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors;Duffner;N Engl J Med.,1993

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity;Acta Neuropathologica Communications;2024-06-21

2. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution;International Journal of Molecular Sciences;2024-04-07

3. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04

4. Innovative Technologies in Pediatric Neuro-Oncology;Annals of the Russian academy of medical sciences;2024-01-22

5. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients;Modern Pathology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3